Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Guell

Nurse Practitioner Little Rock, AR Nurse Practitioner

NPI 1619157591 CMS profile 10644637

2 Lile Ct, Suite 102B, Little Rock, AR 72205

Open in the dashboard

General payments

$4,908

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Guell of Little Rock, AR is reported in the CMS Open Payments database as having received $4,908 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,218 54
2024 General $1,625 70
2023 General $1,498 68
2021 General $567 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Guell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Mary Guell were reported at $1,218. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Mary Guell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $567 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $1,498 $166 $54–$529 $160
2024 $1,625 $173 $55–$556 $164
2025 $1,218 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $887 41 payments
  2. Retrophin, Inc. $824 34 payments
  3. AstraZeneca Pharmaceuticals LP $542 22 payments
  4. Horizon Therapeutics plc $506 27 payments
  5. Novartis Pharmaceuticals Corporation $371 16 payments
  6. Fresenius USA Marketing, Inc. $364 18 payments
  7. Mallinckrodt Hospital Products Inc. $280 10 payments
  8. OPKO Pharmaceuticals, LLC $224 14 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $206 12 payments
  10. Otsuka America Pharmaceutical, Inc. $172 7 payments
  11. Other $530 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,664 197 payments
  2. Education $244 23 payments
Products named General payments · program years 2021–2025
  1. KRYSTEXXA Inflammation/Rare Disease $635 28 payments
  2. KRYSTEXXA Krystexxa $480 26 payments
  3. Velphoro $364 18 payments
  4. ACTHAR $280 10 payments
  5. FARXIGA $248 9 payments
  6. RAYALDEE $224 14 payments
  7. LOKELMA $215 8 payments
  8. Kerendia $206 12 payments
  9. TAVNEOS $172 9 payments
  10. JYNARQUE $172 7 payments
  11. Other $596 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record